Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 16/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 16/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 16/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | DDX3X | O00571 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5622997 | 0.87 | RXRA (0.45) | RXRAGRIN1GRIN2BCA12CA1 | |
| SCHEMBL5624421 | 0.86 | RXRA (0.43) | RXRAGRIN1GRIN2BCA12CA1 | |
| SCHEMBL5623115 | 0.80 | NOTUM (0.51) | RXRAGRIN1GRIN2BCA12CA1 | |
| SCHEMBL5622951 | 0.79 | NOTUM (0.50) | — | |
| SCHEMBL5624193 | 0.77 | NOTUM (0.53) | CA12CA1CA2CA9 | |
| SCHEMBL6619465 | 0.77 | NOTUM (0.35) | RXRAGRIN1GRIN2BCA1CA2 | |
| SCHEMBL5623051 | 0.75 | KDM1A (0.37) | RXRAGRIN1GRIN2BCA12CA1 | |
| SCHEMBL6619456 | 0.75 | MIF (0.41) | — | |
| SCHEMBL5622557 | 0.74 | RXRA (0.49) | RXRAGRIN1GRIN2BCA12CA1 | |
| SCHEMBL5623883 | 0.73 | NOTUM (0.33) | RXRAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202254-B2 | Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-10 | — | — | US | disclosed |
| US-20050209223-A1 | Novel antibacterial compounds: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED | 2005-09-22 | — | — | US | disclosed |
| US-6914058-B2 | 1-(p-(thiomorpholino)phenyl)-1,2,3-triazole derivatives | DR. REDDY'S LABORATORIES, LIMITED (IN) | 2005-07-05 | — | — | US | disclosed |
| US-20050113347-A1 | NOVEL ANTIBACTERIAL COMPOUNDS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LIMITED | 2005-05-26 | — | — | US | disclosed |
| EP-1467977-A1 | NOVEL ANTIBACTERIAL COMPOUNDS:PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | Dr. Reddy's Laboratories Ltd. (IN) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003059894-A1 | NOVEL ANTIBACTERIAL COMPOUNDS:PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | DR.REDDY'S LABORATORIES LTD. (IN) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209223-A1 | Novel antibacterial compounds: process for their preparation and pharmaceutical compositions containing them | CYP3A4, CYP3A43, CYP3A5 | RXRA 2590/4885GRIN1 3906/4885GRIN2B 3893/4885 |
| US-20050113347-A1 | NOVEL ANTIBACTERIAL COMPOUNDS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CYP3A4, CYP3A43, CYP3A5 | RXRA 2590/4885GRIN1 3906/4885GRIN2B 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.